Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
668-02-006 ISMRM Abstract

Evaluating metabolites in metastatic ovarian tumors with and without cytotoxic treatment using 3T MR spectroscopy

Primary: Acquisition & Reconstruction - Spectroscopy and spectroscopic imaging
Secondary: Contrast Mechanisms - Spectroscopy
668-02-006 · Spectroscopy and Spectroscopic Imaging: Applications · Thursday, 14 May, 9:25 AM–10:20 AM · Digital Posters Row I
Keywords: Treatment Response 3.0T 1H MRS Ovarian cancer Cancer metabolism
Accepted
Roshni Parameswaran 1, Imam A Shaik2, Pooja Patkulkar1, Victor A Raj3, Manoj Kumar4, Vivek Tiwari5,6, Anuradha Chandramohan7, Sanhita Sinharay1
1Bioengineering, Indian Institute of Science, Bangalore, India
2Siemens Healthineers, Bangalore, India
3Center for brain research-IISc, Bangalore, India
4Neuroimaging and Interventional Radiology (NIIR), National Institute of Mental Health and Neuro Sciences, Bengaluru, India
5Indian Institute of Science Education and Research (IISER) Berhampur, Odisha, India
6Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Berhampur, Odisha, India
7Radiology, Christian Medical College, Vellore, India
Presenting Author: Roshni Parameswaran

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000 Jan-Apr;2(1-2):166-89. doi: 10.1038/sj.neo.7900081. PMID: 10933075; PMCID: PMC1531872. [doi] [pmid]
2. 2. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol. 2010 Jul;7(7):381-93. doi: 10.1038/nrclinonc.2010.47. Epub 2010 Apr 13. PMID: 20386556 [doi] [pmid]
3. 3. deSouza NM, Rockall A, Freeman S. Functional MR Imaging in Gynecologic Cancer. Magn Reson Imaging Clin N Am. 2016 Feb;24(1):205-222. doi: 10.1016/j.mric.2015.08.008. Epub 2015 Oct 27. PMID: 26613882 [doi] [pmid]
4. 4. Sala E, Kataoka MY, Priest AN, Gill AB, McLean MA, Joubert I, Graves MJ, Crawford RA, Jimenez-Linan M, Earl HM, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology. 2012 Apr;263(1):149-59. doi: 10.1148/radiol.11110175. Epub 2012 Feb 13. PMID: 22332064 [doi] [pmid]
5. 5. Canese R, Pisanu ME, Mezzanzanica D, Ricci A, Paris L, Bagnoli M, Valeri B, Spada M, Venditti M, Cesolini A, Rodomonte A, Giannini M, Canevari S, Podo F, Iorio E. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging. NMR Biomed. 2012 Apr;25(4):632-42. doi: 10.1002/nbm.1779. Epub 2011 Oct 24. PMID: 22020805. [doi] [pmid]
6. 6. McLean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MY, Earl H, Crawford R, Brenton JD, Griffiths JR, Sala E. Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med. 2009 Oct;62(4):855-61. doi: 10.1002/mrm.22067. PMID: 19645005 [doi] [pmid]
7. 7. Ma FH, Li YA, Liu J, Li HM, Zhang GF, Qiang JW. Role of proton MR spectroscopy in the differentiation of borderline from malignant epithelial ovarian tumors: A preliminary study. J Magn Reson Imaging. 2019 Jun;49(6):1684-1693. doi: 10.1002/jmri.26541. Epub 2018 Oct 24. PMID: 30353967 [doi] [pmid]
8. 8. Kolwijck E, Engelke UF, van der Graaf M, Heerschap A, Blom HJ, Hadfoune M, Buurman WA, Massuger LF, Wevers RA. N-acetyl resonances in in vivo and in vitro NMR spectroscopy of cystic ovarian tumors. NMR Biomed. 2009 Dec;22(10):1093-9. doi: 10.1002/nbm.1417. PMID: 19593761 [doi] [pmid]
9. 9. Takeuchi M, Matsuzaki K, Harada M. Clinical value of N-acetyl mucinous compounds and lipid peaks in differentiating benign and malignant ovarian mucinous tumors by MR spectroscopy. Clin Imaging. 2021 Oct;78:127-135. doi: 10.1016/j.clinimag.2021.03.022. Epub 2021 Mar 22. PMID: 33780785 [doi] [pmid]
10. 10. Ibrahim, R.S.M., El Fattah, M.S.A., Metwally, Z.M. et al. Value of magnetic resonance spectroscopy in assessment of adnexal lesions. Egypt J Radiol Nucl Med 50, 90 (2019). https://doi.org/10.1186/s43055-019-0094-8 [doi]
11. 11. Mansour SM, Gomma MMM, Shafik PN. Proton MR spectroscopy and the detection of malignancy in ovarian masses. Br J Radiol. 2019 Sep;92(1101):20190134. doi: 10.1259/bjr.20190134. Epub 2019 Jul 18. PMID: 31287729; PMCID: PMC6732908 [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/668-02-006